SFPM(SZ:002737) Sou Hu Cai Jing·2026-02-09 10:33Core Viewpoint - Kuaihua Pharmaceutical (SZ002737) announced the resignation of its General Manager, Guan Yi, due to personal reasons, while appointing Zhou Jianzhong as the new General Manager to enhance corporate governance and professional management [3][4]. Management Changes - Guan Yi will remain a board member and hold positions in related subsidiaries after resigning as General Manager, with her term originally set from June 25, 2024, to June 25, 2027 [3]. - Zhou Jianzhong, born in 1968 and holding a master's degree from CEIBS, has extensive experience in the pharmaceutical industry, having held various leadership roles in companies such as Wuhan Yuanda Pharmaceutical Group and Jilin Yinglian Biopharmaceutical [3][4]. Shareholding and Compensation - Zhou Jianzhong holds 500 shares in Kuaihua Pharmaceutical and is also the chairman of Kuaihua Group and other subsidiaries [4]. - Guan Yi, the former General Manager, received a pre-tax compensation of 4.8395 million yuan in 2024, the highest among the company's executives, while the current chairman, Guan Yuxiu, received 2.1999 million yuan [5][6]. Financial Outlook - Kuaihua Pharmaceutical expects a net loss attributable to shareholders of 380 million to 240 million yuan for 2025, a significant decline from a profit of 492 million yuan in the previous year [7]. - The adjusted net profit, excluding non-recurring items, is projected to be between 420 million and 285 million yuan, compared to a profit of 345 million yuan in the same period last year [7].